ML-9 – 250 mg

Brand:
Cayman
CAS:
105637-50-1
Storage:
-20
UN-No:
Non-Hazardous - /

ML-9 was originally identified as a selective Ca2+-calmodulin-dependent myosin light chain kinase inhibitor. Concentrations from 10-100 µM are effective at inhibiting vascular smooth muscle tension and reducing intracellular Ca2+ concentrations.{15194} ML-9 also inhibits PKB/Akt activity with an IC50 range of 10-50 µM in rat primary adipocytes. This results in a specific inhibition of insulin-stimulated glucose transport and GLUT4/IGF II receptor translocation to the plasma membrane yet does not interfere with the antilipolytic effect of insulin.{15239} Additionally, ML-9 inhibits other serine/threonine kinases including PKA (IC50 = ~20 µM), p90 S6 (IC50 = ~50 µM), and MAP kinase (IC50 = ~35 µM).{15239}  

 

SKU: - Category:

Description

An inhibitor of PKB/Akt activity (IC50 = 10-50 µM) that inhibits insulin-stimulated glucose transport and intracellular protein translocation; inhibits additional serine/threonine kinases including PKA (IC50 = ~20 µM), p90 S6 (IC50 = ~50 µM), and MAP kinase (IC50 = ~35 µM)


Formal name: 1-[(5-chloro-1-naphthalenyl)sulfonyl]hexahydro-1H-1,4-diazepine, monohydrochloride

Synonyms: 

Molecular weight: 361.3

CAS: 105637-50-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|CaMKs||Product Type|Biochemicals|Kinase Inhibitors|PKA||Product Type|Biochemicals|Kinase Inhibitors|PKB/Akt||Product Type|Biochemicals|Kinase Inhibitors|S6K||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cell Biology|Cell Signaling|Calcium Mobilization||Research Area|Cell Biology|Cell Signaling|cAMP Signaling||Research Area|Cell Biology|Cell Signaling|PI3K/Akt/mTOR Signaling||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes